MedTrace Logo

Fluconazole Pharmacokinetics in Infants

NCT00514358 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2011-07-07

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics of fluconazole in infants and evaluate the dose exposure relationship of current fluconazole dosing in infants who are receiving fluconazole for the prevention or treatment of systemic fungal infections.

Conditions

Sponsors & Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • Pediatric Pharmacology Research Units Network

    collaborator NETWORK

  • Children's Hospital of Philadelphia

    lead OTHER

Principal Investigators

  • Kelly C. Wade, M.D., Ph.D. · Children's Hospital of Philadelphia

  • Peter C Adamson, M.D. · Children's Hospital of Philadelphia

  • Jeffery Barrett, Ph.D. · Children's Hospital of Philadelphia

Eligibility

Max Age
119 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00514358 on ClinicalTrials.gov